LSBCF (LakeShore Biopharma Co) Forward PE Ratio: 0.13 (As of Jul. 01, 2026)


What is LakeShore Biopharma Co Forward PE Ratio?

LakeShore Biopharma Co LSBCF Forward PE Ratio is 0.13 as of Jul. 01, 2026. Among 355 Biotechnology companies, LakeShore Biopharma Co ranks better than 98.03% on this metric.

LakeShore Biopharma Co's Forward PE Ratio for today is 0.13.

LakeShore Biopharma Co's PE Ratio without NRI for today is 0.00.

LakeShore Biopharma Co's PE Ratio (TTM) for today is 0.00.


LakeShore Biopharma Co  (OTCPK:LSBCF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


LakeShore Biopharma Co Forward PE Ratio Related Terms


LakeShore Biopharma Co Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Forward PE Ratio Chart

LakeShore Biopharma Co Annual Data
Trend 2025-03
Forward PE Ratio
18.06

LakeShore Biopharma Co Semi-Annual Data
2025-03
Forward PE Ratio 18.06

LSBCF vs ACUT, PPCB, ENSC: Forward PE Ratio Comparison

For the Biotechnology subindustry, LakeShore Biopharma Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LakeShore Biopharma Co Forward PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Forward PE Ratio falls into.



LakeShore Biopharma Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 0.13 mean?
LakeShore Biopharma Co (LSBCF) has a Forward PE Ratio of 0.13 as of Jul. 01, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on LakeShore Biopharma Co and its competitors. According to the industry distribution chart, LakeShore Biopharma Co ranks #7 out of 355 companies in the Biotechnology industry, placing it in the top 2%.
Is LakeShore Biopharma Co's Forward PE Ratio too high?
LakeShore Biopharma Co's current Forward PE Ratio is 0.13. The Biotechnology industry median Forward PE Ratio is 22.35. LakeShore Biopharma Co's value of 0.13 is 99.4% below this industry median. Based on the distribution chart, LakeShore Biopharma Co ranks #7 out of 355 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does LakeShore Biopharma Co's Forward PE Ratio compare to ACUT and PPCB?
According to the Biotechnology industry distribution chart, LakeShore Biopharma Co ranks #7 out of 355 companies for Forward PE Ratio. This places LakeShore Biopharma Co in the top 2% of its industry — outperforming the majority of peers. The industry median Forward PE Ratio is 22.35. LakeShore Biopharma Co's value of 0.13 is 99.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.35, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LakeShore Biopharma Co's current Forward PE Ratio of 0.13 is 99.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on LakeShore Biopharma Co and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LakeShore Biopharma Co's current Forward PE Ratio is 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Forward PE Ratio of 0.13. The current Forward PE Ratio is 0.13 and 99.4% below the Biotechnology industry median of 22.35. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Forward PE Ratio is 0.13 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.